Key Highlights
- MindMed appoints Dr. Javier Muniz as Vice President of R&D Strategy.
- Dr. Muniz brings 20+ years of expertise in psychiatry and regulatory science.
- He will oversee Phase 3 studies of MM120 ODT for anxiety and depression.
- Former FDA leader in psychiatric drug development and regulatory oversight.
- Dr. Muniz aims to advance psychedelics as transformative treatments in psychiatry.
Source: Business Wire
Notable Quotes
- “Javier’s extensive expertise leading interdisciplinary scientific teams at the U.S. Food and Drug Administration (FDA), combined with his deep experience within the uniformed services in the fields of neuroscience and psychiatry makes him a welcome addition to the MindMed team.” — Dan Karlin, M.D., M.A., Chief Medical Officer at MindMed
- “I am thrilled to join MindMed at such a pivotal moment in the Company’s history, with potential approvals of MM120 ODT for multiple indications on the horizon.” — Javier A. Muniz, M.D., Vice President of R&D Strategy at MindMed
SoHC's Take
MindMed’s appointment of Dr. Javier Muniz signals a strategic move to strengthen its regulatory and scientific leadership as the company progresses toward Phase 3 studies and potential approvals of MM120 ODT. Dr. Muniz’s blend of FDA regulatory expertise and groundbreaking contributions to psychiatric drug development positions MindMed to navigate complex approval pathways and innovate in psychedelics as viable treatments for brain health disorders. This aligns with a broader industry trend of advancing alternative therapies for mental health, with MindMed solidifying its place at the forefront.
